A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV

This is a Phase 2, randomized, open-label, active-controlled, multicenter study to evaluate the safety, efficacy, and PK (Pharmacokinetics) of ISL (Islatravir) +LEN (Lenacapavir). Virologically suppressed PWH (People living With HIV) who meet all eligibility criteria will be randomized in a 2:1 ratio to 1 of the following 2 groups: Treatment Group 1 (n = 50) Oral weekly ISL administered with LEN (ISL+LEN) Treatment Group 2 (n = 25) Oral daily bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)